Cancer genetics

Nature

Volumn 411, Issue 6835, 2001, Pages 336-341

  Ponder, Brace A J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; GENES; GENETIC ENGINEERING; MUTAGENESIS; RESEARCH;

CANCER GENETICS;

TUMORS;

CANCER CELL; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL INTERACTION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MEDICAL GENETICS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; DNA METHYLATION; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; MUTATION; NEOPLASM PROTEINS; NEOPLASMS;

EID: 0035902166     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35077207     Document Type: Review

References (73)

1. Nowell, P. C. The clonal evolution of tumour cell populations. Science 194, 23-28 (1974).
2. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
3. Liotta, L. & Petricoin, E. Molecular profiling of human cancers. Nature Rev. Genet. 1, 48-56 (2000).
4. Baylin, S. B. & Herman, J. G. DNA methylation in tumorigenesis. Trends Genet. 16, 168-174 (2000).
5. Rothman, N. et al. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochem. Biophys. Acta. 1471, C1-C10 (2001).
6. Olden, K. & Wilson, S. Environmental health and genomics: visions and implications. Nature Rev. Genet. 1, 149-153 (2000).
7. Tlsty, T. D. & Hein, P.W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 11, 54-59 (1998).
8. Risch, A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl Cancer Inst. 90, 1774-1768 (1998).
9. Yu, H. & Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst. 92, 1472-1489 (2000).
10. Easton, D. F., Ponder, M. A., Huson, S. M. & Ponder, B. A. J. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am. J. Hum. Genet. 53, 305-313 (1993).
11. Nadeau, J. H. Modifier genes in mice and humans. Nature Rev. Genet. 2, 165-174 (2001).
12. Knudson, A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820-823 (1971).
13. Harris, H. The analysis of malignancy by cell fusion: the position in 1988. Cancer Res. 48, 3302-3306 (1988).
14. Park, M. in The Genetic Basic of Human Cancer (eds Vogelstein, B. & Kinzler, K. W.) 205-228 (McGraw Hill, New York, 1998).
15. Bishop, J. M. Enemies within: the genesis of retrovirus oncogenes. Cell 23, 5-6 (1981).
16. Parada, L. P., Tabin, C. J., Shih, C. & Weinberg, R. A. Human EJ bladder carcinoma oncogene is a homologue of Harvey Sarcoma virus ras gene. Nature 297, 474-477 (1982).
17. Rabbitts, T. H. Chromosomal translocations in human cancer. Nature 372, 143-149 (1994).
18. Brodeur, G. M. & Hogarty, M. D. in The Genetic Basis of Human Cancer (eds Vogelstein, B. & Kinzler, K. W.) 161-172 (McGraw Hill, New York, 1998).
19. Mitelman, F., Meztens, F. & Johansson, B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nature Genet. 13, 417-474 (1997).
20. Gray, J. W. & Collins, C. Genome changes and gene expression in human solid tumours. Carcinogenesis 21, 443-452 (2000).
21. The BAC Resource Consortium. Integration of cylogenetic landmarks into the draft sequence of the human genome. Nature 409, 953-957 (2001).
22. DePinho, R. A. The age of cancer. Nature 408, 248-254 (2000).
23. Comings, D. A general theory of carcinogenesis. Proc. Natl Cancer Inst. 70, 3324-3328 (1973).
24. Cavenee, W. K. et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305, 779-781 (1983).
25. Weinberg, R. A. Tumor suppressor genes. Science 254, 1138-1146 (1991).
26. Fearon, E. R. in: The Genetic Basis of Human Cancer (eds Vogelstein, B. & Kinzler, K. W.) 229-236 (McGraw Hill, New York, 1998).
27. Haber, D. & Harlow, E. Tumor suppressor genes: evolving definitions in the genomic age. Nature Genet. 16, 320-322 (1997).
28. Kinzler, K. W. & Vogelstein, B. Gatekeepers and caretakers. Nature 386, 761-763 (1997).
29. Orborne, R. I. & Hamshere, M. G. A genome-wide map showing common regions of loss of heterozyposity/allelic imbalance in breast cancer. Cancer Res 60, 3706-3712 (2000).
30. Faro, M. I., et al. The murine gene p27 is haploinsufficient for tumour suppression. Nature 396, 177-180 (1998).
31. Rainier, S. et al. Relaxation of imprinted genes in human cancer. Nature 362, 747-749 (1993).
32. Cui, H. et al. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nature Med. 4, 1276-1280 (1998).
33. Herman, J. G. et al. Incidence and functional consequences of hMLH promoter hypermethylation in colorectal carcinoma. Proc. Natl Cancer Inst. 95, 6870-6875 (1998).
34. Chen, R. Z., Pettersson, U., Beard, C., Jackson-Crushy, L. & Jaenisch, R. DNA hypomethylation leads to elevated mutation rates. Nature 395, 89-93 (1998).
35. Jackson-Crushy, I., et al. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nature Genet. 27, 31-39 (2001).
36. Cormier, R. J. & Dove, W. F. Dnmf reduces the net growth rate and multiplicity of intestinal adenomas in C57BI/6-multiple instestinal neoplasia (Min)/+ mice. Cancer Res. 60, 3965-3970 (2000).
37. Issa, J.-P. I. et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genet. 7, 536-540 (1994).
38. Feinberg, A. P. Methylation meets genomics. Nature Genet. 27, 9-10 (2001).
39. Sapienza, C. Genome imprinting, cellular mosaicism and carcinogenesis. Mol. Carcinogenesis 3, 118-124 (1990).
40. Engler, P. et al. A strain-specific modifier on mouse chromosome 4 controls the methylation of independent transgene loci. Cell 65, 939-947 (1991).
41. Silver, A. J. & White, R. Inheritance of allelic blueprint for methylation patterns. Cell 54, 145-152 (1988).
42. Renan, M. J. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinogenesis 7, 139-146 (1993).
43. Suzuki, S. et al. An approach to analysis of large scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res. 60, 5382-5385 (2000).
44. Neal, D. E. & Donovan, J. I. Prostate cancer: to screen or not to screen? Lancet Oncol. 1, 17-24 (2000).
45. El-Omar, E. M. et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398-402 (2000).
46. Williams, J. A. Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. Carcinogenesis 22, 209-214 (2001).
47. Ames, B. N. & Gold, L. S. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science 249, 970-971 (1990).
48. Cordon-Carlo C. & Prives C. At the crossroads of inflammation and tumorigenesis, J. Evp. Med 190, 1367-1370 (1999).
49. Lowenfils, A. B. et al. Hereditary pancreatitis and the risk of pancreatic cancer. J. Natl Cancer Inst. 89, 442-446 (1997).
50. Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011 (1999).
51. Barcellos-Hoff, M. H & Ravani, S. A. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60, 1254-1260 (2000).
52. Sternlicht, M. D. et al. The stromal protease MMP3/Stromelysin-1 promotes mammary carcinogenesis. Cell 96, 137-146 (1999).
53. Coussens, L. M., Tinhl, C. C., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490 (2000).
54. Thomas, M V. et al. A prospective study of endogenous serum hormone concentrations in post-menopausal women on the island of Guernsey. Br. J. Cancer 76, 401-405 (1997).
55. Jernstrom, H. et al. Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in healthy premenopausal women. Cancer Epidemiol. Biomakers Prev. (in the press).
56. Peto, J. in Cancer Incidence in Defined Populations Banbury Report 4 (eds Cairns, J., Lyon, I. L. & Skolnick, M.) (Cold Spring Harbor, New York, 1980).
57. Ponder, B. A. J. Inherited predisposition to cancer. Trends Genet. 6, 213-218 (1990).
58. Vogelstein, B. & Kinzler, K. W. (eds) The Genetic Basis of Human Cancer (McGraw Hill, New York, 1998).
59. Klausner, R. D. Studying cancer in the mouse. Oncogene 18, 5249-5252 (1999).
60. Ponder, B. A . J. Genetic testing for cancer risk. Science 278, 1050-1054 (1997).
61. Chen, F. et al. Germline mutations in the Von Hippel Lindau disease tumour suppressor gene: correlation with phenotype. Hum. Mutat. 5, 66-75 (1995).
62. Kinzler, K. W. & Vogelstein, B. in The Genetic Basis of Human Cancer (eds Vogelslein, B, & Kinzler, K. W.) 565-587 (McGraw Hill, New York, 1998).
63. Eng. C. & The International RET Mutation Corsortium. The relalionship between specific RET protooncogene mutationns and disease phenotype in multiple endocrine reoplasia type 2. J. Am. Med. Assoc. 276, 1575-1579 (1996).
64. Halberg, R. B. et al. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulations and specificity of modifiers. Proc. Natl Acad. Sci. USA 97, 3461-3466 (2000).
65. The Anghan Breast Cancer Study Group. Prevalence of BRCA1 and BRCA2 mutations in a large population based series of breast cancer cases. Br. J Cancer 83, 1301-1308 (2000).
66. Dunning, A. M. et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 8, 843-854 (1999).
67. Chakravarti, A. ... to a future of genetic medicine. Nature 409, 822-823 (2001).
68. Cardon, I., R. & Bell, J. I. Association study designs for complex diseases. Nature Rev. Genet. 2, 91-99 (2001).
69. The International SNP Map Working Group. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933 (2001).
70. Balmain, A. & Nagase, H. Cancer resistance genes in mice: models for the study of tumour modifiers. Trends Genet. 14, 139-144 (1998).
71. Mackay, T. E. C. Quantitation trail loci in Drosphila. Nature Rev. Genet. 2, 11-20 (2001).
72. Bell, J. The new genetics in clinical practice. Br. Med. J. 316, 618-620 (1998).
73. Holtzman, N. A. & Marteau, T. M. Will genetics revolutionize medicine? New Engl. J. Med. 343, 141-144 (2000).